Type 1 Diabetes Research

A Step Into Freedom From T1DM

Tuesday, 23 August 2022

[Review Paper] Nanobiotechnology-Modified Cellular and Molecular Therapy as a Novel Approach for Autoimmune Diabetes Management

Abstract: Several cellular and molecular therapies such as stem cell therapy, cell replacement therapy, gene modification therapy and tolerance induction therapy have been researched to procure a permanent cure for Type 1 Diabetes. However, due to the induction of undesirable side effects, their clinical utility is questionable. These anti-diabetic therapies can be modified with nanotechnological tools for reducing adverse effects by selectively targeting genes and/or receptors involved directly or indirectly in diabetes pathogenesis such as the glucagon-like peptide 1 receptor, epidermal growth factor receptor, human leukocyte antigen [HLA] gene, miRNA gene and hepatocyte growth factor [HGF] gene. This paper will review the utilities of nanotechnology in stem cell therapy, cell replacement therapy, beta-cell proliferation strategies, immune tolerance induction strategies and gene therapy for type 1 diabetes management.


Journal: Pharmaceutical Nanotechnology

Keywords: Autoimmunity; Immunotherapy; Nanocarriers; Stem cell; Tolerance; Type 1 diabetes

Read Full Review Paper

Dr Shivani Desai is a clinical pharmacist, an experienced clinical researcher and academician. She leads preclinical and clinical projects at Serum Institute of India, Pune, India. She expertises in Type 1 Diabetes Mellitus (T1DM) and is currently researching its prevention and reversal.

0 comments:

Post a Comment

Testimonials

Collaborate With Me

Contact Us

SHIVANI DESAI
+91-20-4930-0148
Pune, India